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ANALISIS MULTIFAKTOR DARIPADA PERKAITAN ANTARA ARAS 
SITOKIN DAN PESAKIT DENGAN AUTOANTIBODI ANTI-RO/LA DARI 




Penyakit tisu penghubung (CTDs) adalah salah satu penyakit autoimun 
(AIDs)  yang biasa di negara dan sentiasa dikaitkan dengan tahap autoantibodi anti-
Ro dan anti-La. Kajian semasa dijalankan untuk menentukan analisis multifaktorial 
perkaitan antara sitokin pro- dan anti radang, interleukin (IL)-6 & IL-10 masing-
masing dalam sera wanita positif anti-Ro atau anti-La atau kedua-duanya di utara 
Malaysia. Faktor-faktor seperti jenis penggunaan ubat dan status menopaus dianalisis 
dari sampel yang didiagnosis dengan CTD mengikut tahun perkembangan penyakit. 
Sampel serum dikumpulkan dari hospital kerajaan di wilayah utara Malaysia dan 
sampel ini telah disaring untuk CTD menggunakan enzim immunoassay (EIA). 
Kehadiran corak antibodi anti-nuklear (ANA) diuji dengan ujian imunofluoresensi 
tidak langsung (IFA). Sampel serum positif corak IFA speckled digunakan untuk 
ujian anti-Ro dan anti-La dengan kaedah EIA. Tahap IL-6 dan IL-10 diukur 
menggunakan ELISA. Penemuan kami menunjukkan bahawa purata usia positif anti-
Ro atau anti-La dalam pesakit wanita utara Malaysia adalah 38.1 tahun (SD ± 15.01) 
(n = 106). Perempuan melayu mewakili frekuensi positif antibodi anti-Ro dan anti-
La tertinggi berbanding kaum Cina, India dan kaum lain di Malaysia Utara (72.6% 
berbanding 17.0%, 7.5%, 2.8%). Tiada perkaitan yang ketara di antara tahap sitokin 
dengan jenis ubat dan status hormon (p>0.05). Walau bagaimanapun, keputusan 
menunjukkan bahawa 97.4% pesakit yang didiagnosis dengan autoimun-CTD 
diuruskan dengan ubat berasaskan steroid. Analisis menunjukkan bahawa tahap IL-6 
xvi 
 
dan IL-10 ketara lebih tinggi semasa tahun pertama perkembangan penyakit dan 
kedua-dua sitokin dilaporkan mempunyai tahap tinggi dalam pesakit autoimmune-
CTD menopaus. Tahap purata IL-6 adalah lebih tinggi (70.56 ± 115.59 pg / ml) 
daripada IL-10 (32.96 ± 28.36 pg / ml) dalam positif anti-Ro & La berbanding 
dengan kumpulan kawalan (20.48 ± 15.19 dan 17.10 ± 12.08 pg / ml), masing-
masing (p <0.05). Keputusan kami menunjukkan bahawa IL-6 berkorelasi dengan 
kedua-dua kumpulan (anti-Ro) dan (anti-Ro & La) dengan nilai p=0.045 dan 0.023 
masing-masing. Sebaliknya, IL-10 hanya berkorelasi dalam kumpulan (anti-Ro) (p 
<0.001). Tahap sitokin pro-radang IL-6 telah menunjukkan tahap yang lebih tinggi 
berbanding dengan sitokin anti-radang IL-10. Data-data ini mencadangkan bahawa 
tahap IL-6 boleh secara langsung menyumbang kepada pembentukan autoantibodi 
pada wanita dengan anti-Ro / La. Data-data ini boleh dikemukakan untuk  semakan 
semula protokol dalam menentukan AID atau simptom di Malaysia. Kajian ini juga 
boleh memberi laluan kepada manipulasi penggunaan perencat kepada IL-6 sebagai 




A MULTIFACTORIAL ANALYSIS OF ASSOCIATION BETWEEN 
CYTOKINE LEVELS AND PATIENTS WITH AUTOANTIBODIES ANTI-
RO/LA FROM NORTHERN REGION OF MALAYSIA 
ABSTRACT 
 
Connective tissue diseases (CTDs) are one of the common autoimmune 
diseases (AIDs) in many countries and always associated with high levels of 
autoantibody anti-Ro and anti-La. The current study was conducted to determine the 
multifactorial analysis of association between pro- and anti- inflammatory cytokines, 
interleukin (IL)-6 & IL-10 respectively in sera of female positive anti-Ro or anti-La 
or both in northern Malaysia. Multiple factors including medication and menopause 
status were analyzed from samples diagnosed with CTD at different disease onset. 
Serum samples were collected from government hospitals in northern region 
Malaysia. Serum samples were screened for CTD using enzyme immunoassay (EIA). 
Presence of anti-nuclear antibody (ANA) patterns was tested by indirect 
immunofluorescence assay (IFA). Speckled IFA pattern was tested for anti-Ro and 
anti-La by EIA. Levels of IL-6 and IL-10 were measured using ELISA. Our findings 
showed that the mean age of positive anti-Ro or anti-La in female of Northern 
Malaysia was 38.1 years (SD±15.01) (n=106). Malay female represented the highest 
frequency of positive anti-Ro and anti-la autoantibodies compared to Chinese, Indian 
and other races in North Malaysia (72.6% vs. 17.0%, 7.5%, 2.8%). There are no 
significant associations between cytokine levels with medicines taken and hormonal 
status (p>0.05). However, result indicated that 97.4% of patients diagnosed with 
autoimmune-CTD were managed with steroid-based therapy. Analysis showed that 
mean levels of IL-6 and IL-10 were higher during the first year of disease 
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progressions and both cytokines were reported to have high levels in menopause 
autoimmune-CTD patients. The mean levels of IL-6 was significantly higher (70.56 
± 115.59 pg/ml) than IL-10 (32.96 ± 28.36 pg/ml) in positive anti-Ro & La compared 
to control group (20.48 ± 15.19 and 17.10 ± 12.08 pg/ml), respectively (p<0.05). Our 
result indicated that IL-6 was significantly correlated with both group (anti-Ro) and 
(anti-Ro & La) with p-value of 0.045 and 0.023 respectively. In contrast, IL-10 was 
significantly correlated only in group (anti-Ro) (p<0.001). Level of pro-inflammatory 
cytokine IL-6 was shown to have higher levels compared to anti-inflammatory 
cytokine IL-10. These data suggest that IL-6 levels may directly contribute to the 
formation of autoantibodies in female with anti-Ro/La. These data can be put forth to 
establish revised protocol in determining AID or symptoms in Malaysia. This study 
may also pave way on manipulation of IL-6 inhibitors as therapeutic target molecules 




CHAPTER 1  
 
INTRODUCTION  
1.1 Research Background 
Autoimmune diseases (AIDs) which develop when the immune system 
attacks its own cells and tissues and leads to the production of autoantibodies 
directed againts self proteins (Abbas, Lichtman & Pillai, 2016). AIDs are the third 
most common diseases in United States (US) after cancer and cardiovascular disease 
(NIH, 2000). There are more than 80 types of AIDs such as type 1 diabetes (TID), 
multiple sclerosis (MS), sjogren’s syndrome (SS), rheumatoid arthritis (RA), graves’ 
disease (GD) and systemic lupus erythematosus (SLE) (Simmonds & Gough, 2007). 
Prevalence of AIDs is about 5-8% in general population with predominantly in 
females (78%) (Wang, Wang & Gershwin, 2015). AIDs varies according to ethnicity 
and geographical area (Mackay & Rose, 2006). For instance, Southern European 
countries have a lower event of AIDs compared to North European and North 
American countries (Oliver & Silman, 2009) . A previous study demonstrated that 
Asian and non-Caucasian SLE patients are more prone to severe SLE with poor 
outcomes (Crosslin & Wiginton, 2009). The aetiology of AIDs is not entirely 
elucidated, but evidences suggest that both genetics and environmental factors play 
key roles (Rosenblum, Remedios & Abbas, 2015). Besides that, dysregulation of the 
protective immune responses cuases AIDs. Usually, self-reactive T cells are 
suppressed in a normal state. When the balance between self-reactive and regulatory 
T cells is disturbed, the risk for AIDs onset increases (Kuwabara et al., 2017). 
Malaysia is one of the developing countries in South East Asia comprised of 
three major ethnic groups which is Malay, Chinese, and Indian. A recent study has 




females compared to that of males (14.1%) in which majority of them were Malays 
followed by Chinese, Indians and others (Shaharir et al., 2019). Anisah et al., (2015) 
reported that the prevalence of positive anti-nuclear antibody (ANA) test that were 
used in AIDs detection in North Malaysia region was 6.3% (210/3328) with 
predominantly in females compared to males (75.8% vs. 24.4%). Prevalence of 
positive ANA test was higher in Malay compared to Chinese, Indian and other races 
in Malaysia (52.6% vs. 37.3%, 7.2%, 2.9%, respectively). The most frequently 
observed ANA indirect immunofluorescence assay (IFA) pattern was speckled with 
anti-Ro being the highest autoantibodies detected (Anisah et al., 2015). On the other 
hand, SLE occurrence with positive ANA test in US population was 13.8% with 
higher percentage of risk among females and African Americans (Satoh et al., 2012). 
Basically, cytokine are protein that are secreted by many different cell types 
play crucial role in inflammatory and regulation of immune responses. However, 
there are some adverse effects if it is overproduced. The execessive secretion of 
inflammatory cytokines may lead to several acute and chronic inflammatory 
responses and virtually affect all organ sites and systems (Moudgil & Choubey, 
2011).  The imbalance between production of proinflammatory cytokines such as 
Interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), and anti-inflammatory 
cytokines such as interleukin-10 (IL-10), and transforming growth factor-β (TGF-β) 
contributes to immune dysfunction and thus, contribute to the pathogenesis of certain 
AIDs (Roescher, Tak & Illei, 2010). Previous studies analysed the pattern of 
cytokines production in labial salivary gland of sjogren’s syndrome patients, 
peripheral blood lymphocytes and circulating serum samples from human (Garcic-




The presence of autoantibodies which acts as serological indicator of 
autoimmunity and is often observed in systemic autoimmune diseases such as RA, 
SS, SLE and mixed connective tissue diseases (MCTD) (Gershwin, Meroni & 
Shoenfeld, 2007). Various antigens specific for autoantibodies serve as biomarkers 
that can be used for the diagnosis of AIDs (Satoh et al., 2012). Anti-SSA/Ro (Anti-
Ro) is the most prominent antigen specific for autoantibodies associated with many 
autoimmune diseases including SLE, SS/SLE overlap syndrome, subacute cutaneous 
lupus erythematosus (SCLE), neonatal lupus and primary biliary cirrhosis (Gershwin, 
Meroni & Shoenfeld, 2007). Meanwhile, anti-SSB/La (Anti-La) is often related to SS 
(Franceschini & Cavazzana, 2005). However, anti-Ro and anti-La specific 
autoantibodies may present in both tear and sera of SS patients (Toker, Yavuz & 
Direskeneli, 2004). Several studies have shown that autoantibodies productions were 
associated with elevated levels of inflammatory cytokines (Anaya et al., 2002;  Mozo 
et al., 2014).  
1.2 Justification of study 
It was reported that many cytokines are involved in immune regulation 
activity of various AIDs (Zvezdanović et al., 2006). The cause of sex bias in AIDs is 
more likely to be multifactorial, including differences in the sex chromosomes, sex 
hormones and their receptors (Oliver & Silman, 2009). Thus, this study was 
conducted to determine the multifactorial analysis of association between the 
potential pro- inflammatory (IL-6) and anti-inflammatory (IL-10) cytokines 
production in female patients with anti-Ro and anti-La specific autoantibodies from 
Northern Malaysia. This study may provide data on the anti- and pro-inflammatory 




and La autoantibodies. It is crucial to investigate the importance of balanced 
production of these pro- and anti-inflammatory cytokines and their roles in 
pathogenesis of inflammatory diseases. Multiple factors including medication and 
menopause status and their interrelation with both cytokines secretion in samples 
diagnosed with connective tissue disease (CTD) at different disease onset stages 
were also anaylsed in this study. Since reports on the correlation between cytokines 
profiling and autoantibodies during disease progression in different ethnic groups 
from North Malaysia is limited, this study was conducted to fill such knowledge gap. 
Findings from this study have emphasised the important role of cytokines in 
development of autoantibodies and disease progression and thus may serve as 
potential pharmacological target drug in future. Figure 1.1 show the schematic 
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1.3 Research Objective 
The main objective of this study is to investigate the multifactorial analysis of 
association between cytokine levels and patients with autoantibodies anti-Ro and 
both (anti-Ro and La) from Northern Region of Malaysia. The specific objectives of 
the study were listed below.  
Objective 1: To determine the levels of pro- and anti-inflammatory 
cytokines in female positive anti-Ro and positive both (anti-Ro and La) 
autoantibodies in Northern Malaysia. 
Objective 2: To investigate the multifactorial analysis of female positive 
anti-Ro and positive both (anti-Ro and La) autoantibodies in Northern Malaysia. 
Objective 3: To compare the cytokines level between female positive anti-
Ro and positive both (anti-Ro and La) autoantibodies in Northern Malaysia with 
healthy blood donor. 
Objective 4: To determine the association between cytokine levels and 







CHAPTER 2  
  
  LITERATURE REVIEW 
2.1 General on Immune system and its regulation 
2.1.1 Innate and adaptive immunity 
The physiological function of immune system is to provide protection against 
infections and tissue injuries. The host defense mechanism is classified into innate 
and adaptive immunity. The innate immunity provides an initial protection against 
microbial invasion where the first line of defenses is provided by epithelial barriers 
of skin and mucosal tissues. Epithelial cells locally produced antimicrobial 
substances  called defensins and cathelicidins that kill bacteria and thus serve as 
chemical barrier againts infection. Other mechanisms such as phagocytes, natural 
killer (NK) cells and other innate lymphoid cells (ILCs) and the complement system 
eliminate microbes (Abbas, Lichtman & Pillai, 2016). Figure 2.1 illustrated the 
principal mechanism of innate and adaptive immunity. 
Initially, the invading microbes are recognised by the innate immunitive 
through germ line-encoded pattern-recognition receptors (PRRs). These receptors 
recognise and bind to microbial patterns known as pathogen associated molecular 
patterns (PAMPs) on the surfaces of microbes (Akira, Uematsu & Takeuchi, 2006). 
Toll-like receptors (TLRs) is member of PRRs family and is described as type I 
transmembrane proteins with leucine-rich repeats to optimise host protection 
(Janssens & Beyaert, 2003;  Kawai & Akira, 2010). TLRs facilitate the recognition 
of PAMPs and intracellular Toll-interleukin 1 receptor domains necessary for 







































Phagocytes of the innate immunity which include monocytes, macrophages 
and neutrophils are responsible to recognise, ingest and destroy the invaded 
microbes. Macrophages and neutrophils express surface receptor called lectin 
receptor that binds microbes. This receptor binding activated several enzymes in the 
phagolysosomes such as phagocyte oxidase and nitric oxide synthase (iNOS). Other 
enzymes involved are the lysosomal protease which break down microbial proteins 
and subsequently killed the microbes without destroying the phagocytes (Greenberg 
& Grinstein, 2002).  
Meanwhile, other cellular components of innate immune system such as 
eosinophils, basophils and mast cells are known to eliminate parasitic infections 
(Abbas, Lichtman & Pillai, 2016). Moreover, NK cells (cytolytic effector 
lymphocytes) are capable to induce death of tumor cells and virus infected cells in 
the absence of specific immune response (Vivier et al., 2011). NK cells secrete 
cytokines such as interferon-γ (IFN-γ) in various physiological and pathological 
conditions. IFN-γ stimulate dendritic cells and macrophages to produce two types of 
signals that can activate T lymphocytes. The mechanism occurs in which dendritic 
cells increase their expresion of surface molecules called costimulators. 
Subsequently, the costimulators which bind to receptors on naive T cells and together 
with antigen recognition to activate the T cells (Abbas, Lichtman & Pillai, 2016). 
Secondly, dendritic cells and macrophages secrete cytokines such as IL-1 and IL-6 
which stimulate the differentiation of naïve T cells into effector cells of cell-
mediated adaptive immunity. NK cells also produce TNF-α and IL-10 that act on 





The immune system has developed a highly specialized system for capturing 
and displaying antigens to lymphocytes. Microbes enter through an epithelial barrier 
and are captured by antigen-presenting cells (APC) in the tissue forming dendritic 
cell-associated antigen, subsequently enter lymphatic vessels or blood vessels. The 
microbes and antigens are transported to peripheral lymphoid organs (lymph nodes) 
(Abbas, Lichtman & Pillai, 2016). APC are displayed for recognition by T 
lymphocytes by major histocompatibility complex (MHC) molecules (Greenberg & 
Grinstein, 2002). MHC molecules contain peptide-binding clefts derived from 
protein antigens and recognized antigen-spesific T lymphocytes. Figure 2.2 
illustrated the capture and display of microbial antigens. Thus, the innate immunity 
that recognises the invading pathogens which results in subsequent activation of the 
adaptive immune system.  
Adaptive immunity is mediated by lymphocytes stimulated by microbial 
antigens. The adaptive immunity comprises of humoral immunity and cell-mediated 
immunity. B lymphocytes eliminate extracellular microbes by secreting antibodies 
thus provide humoral immunity, whereas T lymphocytes help to remove eradicate 
intracellular microbes in cell-mediated immunity (Abbas, Lichtman & Pillai, 2016). 
The development of B cells is initiated in bone marrow and is completed in 
peripheral lymphoid tissues (spleen) while T cells develop in thymus (Delves & Oitt, 
2000;  Hoffman, Lakkis & Chalasani, 2016). These “naive” B and T lymphocytes 
then migrate to secondary lymphoid organs (lymph nodes and spleen), where they 
become activated.  
Antibodies (immunoglobulins, Igs) are glycoprotein molecules present on the 














two forms, first as membrane bound antigen receptors on matured B cells known as 
B-cell receptor (BCR) (Hoffman, Lakkis & Chalasani, 2016). Secondly, antibodies 
are presented as secreted protein into the extracellular space where they bind and 
neutralise their target antigens (Hoffman, Lakkis & Chalasani, 2016). BCR and the 
antibodies secreted by matured B cells are able to recognize the conformations of 
macromolecules including proteins, lipids, carbohydrates and nucleic acids hence 
increase its ability to capture diverse formation of microbes (Abbas, Lichtman & 
Pillai, 2016).  
Antibodies consist of two identical heavy chains and two identical light 
chains that are hold together by disulphide bonds as illustrated in figure 2.3, (Delves 
& Oitt, 2000). The N-terminal regions of each chain possesses a variable domain 
with high specificity  to binds antigens. The C-terminals regions of the heavy chains 
are constantly exist in five classes of Igs (IgG, IgA, IgM, IgD, and IgE). The regions 
(designated Fc) are important for the effector functions of the secreted antibodies to 
eliminate pathogens or cause tissue injuries (Hoffman, Lakkis & Chalasani, 2016).  
The process of T-lymphocytes maturation are depends on the specificity of 
different types of T cells recognize to peptides bound expressed by different class of 
MHC molecules (Abbas, Lichtman & Pillai, 2016). The immature T cells also known 
as pro-T cells do not express CD4 and CD8 (CD4- CD8-). Then, the pro-T cells than 
develop into pre-T cells which the TCR β chain is first expressed. The complete T 
cells receptor is expressed in double positive T cells (CD4+CD8+) immature T cells.  
Mature T cells  develop into single positive T cells (CD4+ T cells) and (CD8+ T cells) 
through positive selection (Abbas, Lichtman & Pillai, 2016). Figure 2.4 showed the 





Figure 2.3 Structure of antibodies 
 









































The CD4+ T cells recognise antigens presented on MHC class II molecules by 
antigen presenting cells including dendritic cells, macrophages and B cells which in 
turn results in activation of the CD4+ T cells into effector cells. Thereafter, these 
cells differentiate into different T helper (Th) cell subset, including Th1, Th2 and 
Th17 helper T cells that produce dictinct cytokines profiles and response to the 
specific type of microbes. For example Th1 secrete IFN-γ cytokine and express 
CD40 ligands which activate macrophage  to kill phagocytosed microbes (House & 
Descotes, 2007). Meanwhile, mature CD8+ T cells recognise antigens presented on 
MHC Class I molecules, and capable of becoming cytotoxic T lymphocytes on 
activation to kill virus infected cells (Delves & Oitt, 2000). Immature T-lymphocytes 
that strongly recognized self-antigens undergo negative selection to prevent 
lymphocytes that could react in a harmful way to its own protein (Abbas, Lichtman 
& Pillai, 2016).  
2.1.2 The importance of immune regulation 
A remarkable characteristic of normal immune system is to only react 
towards an enormous variety of microbes without affecting the individual’s own 
(self) antigens. This unresponsiveness to self-antigens is termed as immune tolerance 
(Abbas, Lichtman & Pillai, 2016). A complex system of immuno-competent cells 
with proper regulatory function is important to minimise clonal expansion of auto 
reactive cells to prevent tissue and organ damages (Szodoray et al., 2009). 
Immunological self-tolerance is an adaptive (or acquired) process to avoid self-
destruction by auto-reactive T and B cells (Sakaguchi, Wing & Yamaguchi, 2009). 
There are two principal mechanism of central tolerance in T lymphocyte. Firstly, 




& Pillai, 2016). Negative selection are a strong recognition of immatue T cells 
specific to self antigen that displayed peptide bound to self MHC triggers program 
cell death (apoptosis). Secondly are the development of CD4+ regulatory T cells. 
Some immature T cells that do not die by apoptosis will develop into regulatory T 
cells and enter peripheral tissues (Abbas, Lichtman & Pillai, 2016).  
Peripheral tolerance also prevent T cell response to self antigen and there are 
three major mechanism take part in peripheral tolerance. First of all, anergy are 
referred as long-lived unresponsivenes of T cells to self antigens. This event occur 
when antigen recognition towards T cells happen without adequate costimulation (B7 
protein) since there are no microbial presentation (Sakaguchi, Wing & Yamaguchi, 
2009). Second mechanism are the immune suppresion by regulatory T cells which 
include CD4+ T cells that express high level of CD25 (IL-2α receptor). IL-2 are 
importance cytokine involved in proliferatation of  T cells and play a responses by 
maintaining funcitional of T regulatory (Tregs) (Sakaguchi, Wing & Yamaguchi, 
2009). Besides, Treg cells are regarded as suppressors, since they are involved in 
maintaining tolerance to self-antigens and produce anti-inflammatory cytokines such 
as IL-10 and TGF-β (Jin & Yu, 2013). Tregs are comprised of two subgroups, 
natural Tregs (nTregs) and inducible Tregs (iTregs) (Gol-Ara et al., 2012). For 
instance, subsets of Tregs are Tr1 regulatory cells, CD8+ Tregs, nTregs, Th3 cells 
and natural killer like T (NKT) cells (Gol-Ara et al., 2012). The third mechanism of 
peripheral tolerance in T cells are apoptosis of mature lymphocyte caused by the 
engagement of death receptor ligand that result in deletion (Abbas, Lichtman & 
Pillai, 2016). In the case of B cells, central tolerance occur in the bone marrow, 
where immature B cells that recognise self-antigens switch their specificity by 




immature B cells that strongly recognise self-antigens will receive death signals and 
die through apoptosis (deletion) (Abbas, Lichtman & Pillai, 2016). Figure 2.5 
illustrated the mechanism of central and peripehral tolerance of B and T cells to self 
antigens. 
2.1.3 Loss of immune regulation 
One of the key feature of the immune system is its ability to distinguish ‘self’ 
molecules from ‘non-self’ molecules (Abbas, Lichtman & Pillai, 2016). Despite the 
immune system’s efficiency in eliminating auto reactive B and T cells through 
central and peripheral tolerance, sometimes the immune system fails to distinguish 
between self and non-self, molecules which results in condition known as 
autoimmunity. While the recognition of foreign antigens is vital to initiate immune 
responses againts pathogens, the failure to recognise self-antigens results in AID as 
illustrated in Figure 2.6. AIDs results from multiple genetic alterations that are likely 
to be influenced by environmental factors (Elkon & Casali, 2008). Besides, presence 
of human leukocyte antigen (HLA) genes was shown to be a risk factors that enhance 
the development of AIDs including SS (Hernández-Molina et al., 2015). 
Moreover, an infections may activate APC causes induction of costimulator 
(B7 and CD28). Thus, APCs present self antigens to self-reactive T cells hereby 
attack self tissue triggering the development of AIDs (Abbas, Lichtman & Pillai, 
2016). Furthermore, some microbial infections produce peptide antigens that cross 
reacts with self-antigens, a term called molecular mimicry that may promote 






Figure 2.5 Central and peripheral tolerance to self-antigen.  
Central tolerance: Immature lymphocytes specific for self-antigens may encounter 
these antigens in the generative (central) lymphoid organs and are deleted; B 
lymphocytes change their specificity (receptor editing); and some T lymphocytes 
develop into regulatory T cells. Some self-reactive lymphocytes may complete their 
maturation and enter peripheral tissues. Peripheral tolerance: Mature self-reactive 
lymphocytes may be inactivated or deleted by encounter with self-antigens in 
peripheral tissues or suppressed by regulatory T cells. Figure adapted from (Abbas, 






Figure 2.6 Postulated mechanisms of autoimmunity.  
In this proposed model of an organ-specific T cell-mediated autoimmune disease, 
various genetic loci may confer susceptibility to autoimmunity, in part by influencing 
the maintenance of self-tolerance. Environmental triggers, such as infections and 
other inflammatory stimuli, promote the influx of lymphocytes into tissues and the 
activation of antigen-presenting cells (APCs) and subsequently of self-reactive T 









2.2 Pathogenesis of autoimmune diseases (AIDs) 
2.2.1 Autoantibodies production  
Autoantibodies have been defined as immunoglobulins reacting againts self 
molecules (Gershwin, Meroni & Shoenfeld, 2007). Autoantibody production against 
cellular components is the serologic indicator of autoimmunity and is commonly 
seen in systemic AIDs (Satoh et al., 2012). AIDs generally develops with multiple 
and high titre of autoantibodies and detected in healthy individuals (Brandt et al., 
2015). Collectively, ANA prevalence in the US was higher among middle age of 
females with anti-Ro being the most common specific autoantibodies (Satoh et al., 
2012). Previous study was performed in Thailand (1987) found that the frequency of 
ANA positive among Thailand patients with different CTD found to be 11.6% 
(Sucheela et al., 1987). 
Nucleus is one of the main structure in the intracellular targets of the 
autoimmune responses response (Gershwin, Meroni & Shoenfeld, 2007). Basically, 
immunologist normally will referred to the initial positive of ANA testing (titre of 
antibodies) from human sera using IFA method. Besides, this fluoresecence 
microscopy will also provide information on staining pattern with autoantigen 








Table 2.1 Antinuclear antibody staining patterns at IFA and specificities of major 
types of ANA producing these patterns. 
 
IIF Pattern in Hep2 cells   Autoantigen Specificities 
Rim-like     Nuclear pore complexes (gp210,p62, Tpr) 
      Lamins A, B, C 
Inner nuclear membrane (LAP1, LAP2, 
LBR and MAN1) 
Homogenous     Chromatin 
      ds DNA 
      Histone 
      Scl70 
Centromere     CENP-A, B, C 
Speckled     n RNP 
      Sm 
      PCNA 
      La (SSB) 
      Ro (SSA) 
      Ku 
      RNAP II 
Nucleolar     Fibrillarin 
      U3 RNP 
      NOR90 
      B23 
      RNAP I-III 
      Th/To 
      PM-Scl 
Nuclear Dot     Sp100 
      PML 
      SUMO 









2.2.2 Anti-Ro and Anti-La antibodies 
The presence of anti-Ro and/or anti-La specific autoantibodies are reffered 
classification criteria in SS diagnosis proposed by American College of 
Rheumatology (ACR) (Takagi et al., 2014). The frequency of anti-Ro and anti-La  
specific autoantibodies present in sera of SS patients were estimated to be 96% and 
87% respectively (Harley et al., 1986). Anti- Ro and anti-La specific autoantibodies 
were reported to be detected in salivary and lacrimal glands extracts from SS patients 
(Franceschini & Cavazzana, 2005).  
In 1979, Ro and La have been described to be antigenically identical to SSA 
and SSB respectively. Therefore, these antigens are also known as SSA/Ro and 
SSB/La (Alspaugh & Maddison, 1979). The Ro/La system is regarded as 
heterogeneous antigenic complex which the Ro antigen is comprised of two different 
Ro proteins of 52 and 60kDa and the latter binds small cytoplasmic ribonucleic acid 
(RNA) known as hY-RNAs (Franceschini & Cavazzana, 2005). Meanwhile, La 
antigen which was formerly named as Ha is a 48kDa phosphorylated protein present 
in nucleus and cytoplasm and it was shown to be able to bind various RNA 
molecules including RNA polymerase III (Franceschini & Cavazzana, 2005). The 
binding of 60kDa Ro antigen with small hY-RNAs is also associated with La at 
various sites, as shown in Figure 2.3. 
Autoantibodies specific to anti-Ro is often detected in AIDs such as SLE, 
SS/SLE overlapping syndrome and subacute cutaneous LE (SCLE) (Franceschini & 
Cavazzana, 2005). In contrary, anti-La is mostly found in SS patients (Franceschini 
& Cavazzana, 2005). Furthermore, anti-Ro specific antibodies were detected alone in 




anti-Ro specific antibodies (Gottenberg et al., 2003). In Malaysia, the prevalence of 
test positive results for anti- Ro and anti- La in SLE patients was reported to be 36% 
and 8%, respectively. The occurence of anti-Ro in western countries was similar to 
that of in Malaysia (Wang, Ooi & Wang, 1996).  
A previous study have shown that cultured epithelial cells from SS patients 
constitutively produced exosomes that contain major autoantigens Ro, La and Sm. 
The mechanism may involve a pathway where intracellular autoantigens are 
presented to the immune system (Gershwin, Meroni & Shoenfeld, 2007). Besides, 
there are correlation between anti-Ro specific antibodies with photosensitive rashes 




Figure 2.7 This figure illustrates the Ro/La RNA complex 
Figure was adapted from (Franceschini & Cavazzana, 2005) 
2.2.3 AIDs predominance in females   
Women are predominantly affected by various types of AIDs worldwide. 
This corresponds to a study conducted in Caucasian SLE patients where most of 




addition, previous study showed that primary SS was mostly diagnosed in women 
with average age of 56.2 years old (Qin et al., 2014). The sex hormones (oestrogen, 
androgens and prolactin) play some vital roles in enhancing susceptibility towards 
AIDs. Oestrogen in females activates B cells which then results in increased levels of 
antibodies and autoantibodies production whereas androgens suppress maturation of 
B cell and production of antibodies (Brandt et al., 2015). Furthermore, oestrogen and 
prolactin cooperatively to increase autoantibody levels especially Ro and La specific 
autoantibodies. Prolactin is capable to alter immune functions via prolactin receptors 
expressed on mast cells, macrophages, T and B cells and thus enhance the production 
of autoantibodies (Brandt et al., 2015). The X chromosomes in females contain 
immune-associated genes that capable to establish immune tolerance. This genetic 
factor may have contributed to the enhanced risk of AIDs in female since more X 
chromosomes are present in females (XX) compared to males (XY) (Oliver & 
Silman, 2009). Besides, SS in women is associated with other AIDs which present 
primarily in women such as RA, thyroiditis and Raynaud’s phenomenon (Brandt et 
al., 2015). 
2.3 The role of cytokines in pathogenesis of AIDs 
2.3.1 The structures, functions and origin of cytokines 
Cytokines are large group of secreted proteins with diverse structures and 
functions. They regulate and coordinate activities of the cells of innate and adaptive 
immunity (Abbas, Lichtman & Pillai, 2016). All cytokines are pleiotropic and they 
are capable to interact with various cellular targets through specific receptors 
expressed on the surface of cells (House & Descotes, 2007). They function as a 
